Thursday, November 23, 2023
Today, XtalPi announced a Memorandum of Understanding (MOU) with the Experimental Drug Development Centre (EDDC), Singapore's national drug discovery and development platform hosted by A*STAR. This collaboration builds upon their ongoing partnership initiated in December 2022, now encompassing potential projects focusing on applying automated synthesis solutions and large language models in pharmaceutical research. The primary goal is to expedite the transformation of scientific discoveries into robust pipeline assets by advancing intelligent automated pharmaceutical research.
According to the MOU, XtalPi and EDDC will explore collaborations in automated chemical compound synthesis and AI-driven drug discovery. This includes using XtalPi's robotics and AI-driven drug design capabilities in EDDC's R&D, covering automated library synthesis and other drug chemical synthesis services. XtalPi's automated workstations are positioned to offer remote support, generating substantial high-quality data to enhance EDDC's current drug development processes. The collaboration aims to leverage robotics and AI for developing cutting-edge computational tools and industry practices in therapeutic discovery.
Furthermore, the partners will jointly explore the potential of advanced AI models, including large language models (LLM), to drive biopharmaceutical innovation. The objective is to extract valuable insights and develop robust methodologies in areas such as target discovery and molecular design by integrating high-throughput automated experiments, cellular phenotypes, and multi-omics data. This collaborative effort capitalizes on XtalPi's expertise in artificial intelligence and EDDC's wealth of R&D data and experience in preclinical and clinical research.
XtalPi offers a digital twin of AI and robotics uniquely equipped to tackle diverse research challenges at EDDC. Together, we aim to enhance EDDC's research throughput, efficiency, and success rate, expediting the translation of meaningful research into impactful medicines for patients globally."
EDDC, shared his excitement about the partnership, saying, "We are thrilled to embark on this journey with XtalPi to enhance our industry know-how in drug discovery and development with XtalPi's automation resources and AI capabilities. Through this partnership, we aim to accelerate the drug discovery process at EDDC, progressing towards swiftly delivering novel therapies for patients worldwide."
Source: prnasia.com
